HUP0002381A1 - Apolipoprotein A-1 agonista hatású peptidszármazékok, ezek lipidekkel alkotott komplexei, valamint ezeket tartalmazó gyógyászati készítmények - Google Patents

Apolipoprotein A-1 agonista hatású peptidszármazékok, ezek lipidekkel alkotott komplexei, valamint ezeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0002381A1
HUP0002381A1 HU0002381A HUP0002381A HUP0002381A1 HU P0002381 A1 HUP0002381 A1 HU P0002381A1 HU 0002381 A HU0002381 A HU 0002381A HU P0002381 A HUP0002381 A HU P0002381A HU P0002381 A1 HUP0002381 A1 HU P0002381A1
Authority
HU
Hungary
Prior art keywords
apolipoprotein
peptide derivatives
complexes
pharmaceutical compositions
agonist peptide
Prior art date
Application number
HU0002381A
Other languages
English (en)
Inventor
Klaus Buttner
Isabelle Cornut
Jean-Louis Dasseux
Jean Dufourcq
Gunther Metz
Renate Sekul
Original Assignee
Klaus Buttner
Isabelle Cornut
Jean-Louis Dasseux
Jean Dufourcq
Gunther Metz
Renate Sekul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klaus Buttner, Isabelle Cornut, Jean-Louis Dasseux, Jean Dufourcq, Gunther Metz, Renate Sekul filed Critical Klaus Buttner
Publication of HUP0002381A1 publication Critical patent/HUP0002381A1/hu
Publication of HUP0002381A3 publication Critical patent/HUP0002381A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgyát a humán apolipoprotein A-I (ApoA-I) szerkezeti ésfarmakológiai tulajdonságait utánzó (I) általános képletű 15-29 tagúpeptidek vagy peptidanalógok képezik, ahol Z1-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12<I*U ^*X*O*A*>-X13-X14-X15-X16--X17-X18-X19-X20-X21-X22-X<I!U!VX!O!A >23-Z2 (I) X1-X23 jelentése egymástól függetlenül valamely aminosav, Z1 jelentése H2N- vagy RC(O)NH- csoport, és Z2 jelentése -C(O)NRR, -C(O)OR vagy -C(O)OH csoport. A találmánytárgyát képezi még a fenti peptidszármazékokat tartalmazó ApoA-agonista-lipid komplexek, valamint ezeket tartalmazó gyógyászatikészítmények. Ó
HU0002381A 1997-09-29 1998-09-28 Apolipoprotein a-1 agonist peptide derivatives, complexes thereof and pharmaceutical compositions comprising their HUP0002381A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/940,095 US6004925A (en) 1997-09-29 1997-09-29 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
PCT/US1998/020327 WO1999016459A1 (en) 1997-09-29 1998-09-28 Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders

Publications (2)

Publication Number Publication Date
HUP0002381A1 true HUP0002381A1 (hu) 2000-10-28
HUP0002381A3 HUP0002381A3 (en) 2001-05-28

Family

ID=25474217

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002381A HUP0002381A3 (en) 1997-09-29 1998-09-28 Apolipoprotein a-1 agonist peptide derivatives, complexes thereof and pharmaceutical compositions comprising their

Country Status (20)

Country Link
US (11) US6004925A (hu)
EP (2) EP1854471B1 (hu)
JP (1) JP2001518282A (hu)
KR (1) KR100650929B1 (hu)
CN (1) CN1247254C (hu)
AT (2) ATE383865T1 (hu)
AU (3) AU746090B2 (hu)
CA (1) CA2304805A1 (hu)
DE (2) DE69841030D1 (hu)
DK (2) DK1854471T3 (hu)
ES (2) ES2300125T3 (hu)
HU (1) HUP0002381A3 (hu)
IL (1) IL135318A0 (hu)
NO (1) NO20001599L (hu)
NZ (1) NZ503717A (hu)
PL (1) PL196675B1 (hu)
PT (1) PT1019073E (hu)
RU (1) RU2215747C2 (hu)
UA (1) UA71553C2 (hu)
WO (1) WO1999016459A1 (hu)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
WO2000059855A1 (en) * 1999-04-01 2000-10-12 Esperion Therapeutics, Inc. Ether compounds, compositions, and uses thereof
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7407662B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
DE60143122D1 (de) * 2000-11-10 2010-11-04 Hoffmann La Roche Apolipoprotein-Konstrukte
CA2428114C (en) 2000-11-10 2013-07-23 Proteopharma Aps Apolipoprotein analogues
US6991727B2 (en) * 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
WO2003000372A2 (en) * 2001-06-25 2003-01-03 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
PL369545A1 (en) * 2001-09-28 2005-05-02 Esperion Therapeutics, Inc. Methods and apparatus for extrusion of vesicles at high pressure
WO2003026492A2 (en) * 2001-09-28 2003-04-03 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
JP2005511713A (ja) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
IL165253A0 (en) * 2002-05-17 2005-12-18 Esperion Therapeutics Inc Methods and compositions for the treatment of ischemic reperfusion
BR0310099A (pt) * 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
NL1020962C2 (nl) * 2002-06-28 2003-12-30 Tno Therapie en prognose/monitoring bij sepsis en septische shock.
WO2004004774A2 (en) * 2002-07-03 2004-01-15 Esperion Therapeutics, Inc. Compositions comprising panthetine for the treatment of dyslipidemia
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
EP1562555A2 (en) * 2002-10-24 2005-08-17 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
MXPA05007674A (es) * 2003-01-23 2005-09-22 Esperion Therapeutics Inc Compuestos de hidroxilo y composiciones para el manejo del colesterol y usos relacionados.
PT1641421T (pt) 2003-07-03 2019-03-27 Hdl Therapeutics Inc Métodos e dispositivos para criar derivados de partículas de hdl com conteúdo de lípidos reduzido
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
AU2004299486B2 (en) * 2003-12-15 2011-05-19 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
EP1699527A1 (en) 2004-01-02 2006-09-13 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
WO2005097206A2 (en) * 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
EP1602931A1 (en) * 2004-06-03 2005-12-07 Universiteit Leiden SR-A antagonists
UY28952A1 (es) * 2004-06-09 2006-01-31 Avanir Pharmaceuticals Mediadores del transporte inverso de colesterol para el tratamiento de la hipercolesterolemia
UY28953A1 (es) * 2004-06-09 2006-01-31 Avanir Pharmaceuticals Derivados heterocíclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas
CA2568539A1 (en) * 2004-06-09 2005-12-29 Avanir Pharmaceuticals Small molecules for treatment of hypercholesterolemia and related diseases
CA2579676A1 (en) 2004-09-08 2007-02-15 Hana Golding Compositions and methods for the detection of hiv-1/hiv-2 infection
WO2006034056A2 (en) * 2004-09-16 2006-03-30 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
ATE469174T1 (de) 2004-10-15 2010-06-15 Us Gov Health & Human Serv Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
BRPI0517148A (pt) 2004-12-06 2008-09-30 Univ California método de aperfeiçoamento da estrutura e/ou função arterìola; agente ativo e kit para tratamento
US7759315B2 (en) 2005-03-09 2010-07-20 Csl Behring Ag Treatment of inflammatory conditions of the intestine
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
EP1890715A4 (en) * 2005-04-29 2009-10-28 Univ California PEPTIDES AND PEPTIDE MIMETICS FOR TREATMENT BY INFLAMMATORY REACTION OF CHARACTERIZED PATHOLOGIES
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2006125304A1 (en) * 2005-05-25 2006-11-30 Liponex, Inc. Pharmaceutical compositions for treating or preventing coronary artery disease
GR1005428B (el) * 2005-05-27 2007-02-01 Χαραλαμπος Αλεξοπουλος Συνθετικα λιποπεπτιδια με αντιαθηρογονο δραση, που εμποδιζουν την οξειδωση της λιποπρωτεϊνης χαμηλης πυκνοτητας (ldl) και αναστελλουν την απενεργοποιηση του ενζυμου της paf ακετυλοϋδρολασης (paf-ah)
NZ565955A (en) 2005-08-22 2011-08-26 Melior Pharmaceuticals I Inc Methods and formulations for modulating lyn kinase activity and treating related disorders
GB0602598D0 (en) * 2006-02-09 2006-03-22 Cheesmond David Quick change front F2 sidecar
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
TW200744627A (en) * 2006-02-21 2007-12-16 Pfizer Prod Inc Methods for the treatment of macular degeneration and related eye conditions
WO2007137400A1 (en) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Method and compound for the treatment of valvular stenosis
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
WO2007149355A2 (en) * 2006-06-16 2007-12-27 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
CA2659655A1 (en) 2006-08-08 2008-02-21 Alan M. Fogelman Salicylanilides enhance oral delivery of therapeutic peptides
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
CA2931881C (en) * 2007-01-31 2018-12-11 Nutrition 21, Inc. Use of chromium histidinate for treatment of cardiometabolic disorders
KR20100014480A (ko) * 2007-02-20 2010-02-10 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성제의 확인 방법
EP2465519B1 (en) 2007-03-01 2013-10-23 CSL Limited Treatment of endothelial dysfunction in diabetic patients
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
NZ579288A (en) * 2007-07-23 2012-06-29 Melior Discovery Inc Methods of activating irs-1 and akt
US8431529B2 (en) * 2007-07-31 2013-04-30 Sanford-Burnham Medical Research Institute Bi-dentate compounds as kinase inhibitors
US7919581B2 (en) * 2007-07-31 2011-04-05 Burnham Institute For Medical Research Bi-dentate compounds as kinase inhibitors
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
AU2008296444A1 (en) * 2007-08-29 2009-03-12 The Regents Of The University Of California Salicylanilide modified peptides for use as oral therapeutics
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
SG10201901089TA (en) 2008-11-10 2019-03-28 Arbutus Biopharma Corp Novel lipids and compositions for the delivery of therapeutics
CA2788223A1 (en) 2009-01-23 2010-07-29 Institut De Cardiologie De Montreal Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
SI2396017T1 (sl) * 2009-02-16 2015-12-31 Cerenis Therapeutics Holding Sa Mimika apolipoproteina A-1
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
SG10201402054UA (en) 2009-05-05 2014-09-26 Muthiah Manoharan Lipid compositions
EP2433132B1 (en) 2009-05-21 2018-02-21 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compositions and methods for the detection of hiv-1/hiv-2 infection
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
HUE056773T2 (hu) 2009-06-10 2022-03-28 Arbutus Biopharma Corp Továbbfejlesztett lipid készítmény
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120270771A1 (en) * 2009-09-30 2012-10-25 Snu R&Db Foundation Apolipoprotein a-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising same
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
AU2010330814B2 (en) 2009-12-18 2017-01-12 Acuitas Therapeutics Inc. Methods and compositions for delivery of nucleic acids
EP2517013A4 (en) * 2009-12-23 2013-07-17 Artery Therapeutics Inc DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH DEFICIENT REVERSE CHOLESTER INTRANSPORT
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
IL300109A (en) 2010-06-03 2023-03-01 Alnylam Pharmaceuticals Inc Biodegradable lipids for the transfer of active substances
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
US8728749B2 (en) 2010-12-31 2014-05-20 Bruce J. Auerbach Detection of LCAT activity
EP3202760B1 (en) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
RU2017126088A (ru) 2011-02-07 2019-01-31 Серени Терапеутикс Холдинг С.А. Липопротеиновые комплексы и их получение и применения
CA2828572C (en) 2011-03-01 2021-02-23 Jds Therapeutics, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
AU2012315965A1 (en) 2011-09-27 2014-04-03 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted PEGylated lipids
CA2857163A1 (en) * 2011-11-30 2013-06-06 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition for preventing or treating hyperlipidemia
CA2859156C (en) 2011-12-12 2020-10-06 Melior Pharmaceuticals I, Inc. Treatment of type i and type ii diabetes
CA2902209A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
EP3137899A2 (en) 2014-05-02 2017-03-08 Cerenis Therapeutics Holding SA Hdl therapy markers
US10220046B2 (en) 2014-07-14 2019-03-05 The Regents Of The University Of Michigan Compositions and methods for disease treatment using nanoparticle delivered compounds
EP3189069B1 (en) 2014-07-31 2024-10-23 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
CN107530307A (zh) 2015-03-13 2018-01-02 艾斯柏伦治疗公司 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
US11642419B2 (en) * 2015-03-25 2023-05-09 The Regents Of The University Of Michigan Compositions and methods for treating cardiovascular related disorders
CA2979712C (en) 2015-03-25 2024-01-23 The Regents Of The University Of Michigan Nanoparticle compositions for delivery of biomacromolecules
CA2991655A1 (en) 2015-07-10 2017-01-19 Peptinovo Biopharma, Llc Formulations for improving the efficacy of hydrophobic drugs
WO2017139337A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
CA3032229A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sa Therapeutic combinations to treat red blood cell disorders
FR3061715B1 (fr) * 2017-01-12 2021-07-30 Institut National Univ Jean Francois Champollion Peptide immunomodulateur
US11027052B2 (en) 2017-11-22 2021-06-08 HDL Therapuetics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
NZ758966A (en) 2017-04-10 2024-08-30 Board Of Supervisors Of Louisiana State Univ And Agricultural And Mechanical College Treatment of adipocytes
US20190048049A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Sa Cargomers
AU2018360730A1 (en) 2017-10-30 2020-05-21 Montreal Heart Institute Methods of treating elevated plasma cholesterol
EP3731814A4 (en) 2017-12-28 2021-09-29 HDL Therapeutics, Inc. PROCESSES FOR THE STORAGE AND ADMINISTRATION OF HIGH DENSITY PRE-BETA LIPOPROTEINS EXTRACTED FROM HUMAN PLASMA
CN110294791B (zh) * 2019-06-13 2023-02-21 倪京满 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
EP3986860A1 (en) 2019-06-21 2022-04-27 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same
AU2021256086A1 (en) 2020-04-16 2022-12-15 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
WO2022069942A2 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
MX2023012223A (es) 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (hu) * 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (en) * 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
DE3241102A1 (de) * 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
CA2137814A1 (en) * 1992-06-12 1993-12-23 Maryvonne Rosseneu New peptides and proteins, process for their preparation and their use as cholesterol acceptors
US5344822A (en) * 1992-08-12 1994-09-06 The Rogosin Institute Methods useful in endotoxin prophylaxis and therapy
US5674855A (en) * 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
FR2723741A1 (fr) * 1994-08-16 1996-02-23 Fournier Sca Lab Peptides inhibiteurs de la proteine de transfert des esters de cholesterol et leur utilisation en therapeutique
FR2734568B1 (fr) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
CA2249459A1 (en) 1996-03-29 1997-10-09 Dario Boffelli Amphipathic molecules as cholesterol and other lipid uptake inhibitors
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
WO1998029736A1 (en) * 1996-12-31 1998-07-09 Genometrix Incorporated Multiplexed molecular analysis apparatus and method
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6977155B2 (en) * 2000-08-10 2005-12-20 Corning Incorporated Arrays of biological membranes and methods and use thereof

Also Published As

Publication number Publication date
PL196675B1 (pl) 2008-01-31
DK1019073T3 (da) 2008-05-19
US6716816B1 (en) 2004-04-06
US20030203842A1 (en) 2003-10-30
US6376464B1 (en) 2002-04-23
DE69841030D1 (de) 2009-09-10
HUP0002381A3 (en) 2001-05-28
ATE437648T1 (de) 2009-08-15
EP1019073A1 (en) 2000-07-19
UA71553C2 (uk) 2004-12-15
AU2005201985B2 (en) 2007-11-01
WO1999016459A1 (en) 1999-04-08
US6573239B1 (en) 2003-06-03
CN1247254C (zh) 2006-03-29
CA2304805A1 (en) 1999-04-08
JP2001518282A (ja) 2001-10-16
DE69839014D1 (de) 2008-03-06
AU746090B2 (en) 2002-04-18
NO20001599D0 (no) 2000-03-28
US6630450B1 (en) 2003-10-07
ES2300125T3 (es) 2008-06-01
CN1280501A (zh) 2001-01-17
US6753313B1 (en) 2004-06-22
EP1019073B1 (en) 2008-01-16
NO20001599L (no) 2000-05-02
AU2005201985A1 (en) 2005-05-26
NZ503717A (en) 2002-08-28
US7189689B2 (en) 2007-03-13
AU9779098A (en) 1999-04-23
PL339629A1 (en) 2001-01-02
US7312190B2 (en) 2007-12-25
US20040181034A1 (en) 2004-09-16
US7307058B2 (en) 2007-12-11
RU2215747C2 (ru) 2003-11-10
US6602854B1 (en) 2003-08-05
KR20010030802A (ko) 2001-04-16
EP1019073A4 (en) 2004-11-03
DE69839014T2 (de) 2009-01-08
EP1854471B1 (en) 2009-07-29
KR100650929B1 (ko) 2006-11-29
US6004925A (en) 1999-12-21
US20050215467A1 (en) 2005-09-29
ATE383865T1 (de) 2008-02-15
US6329341B1 (en) 2001-12-11
DK1854471T3 (da) 2009-11-23
AU2002300785B2 (en) 2005-02-10
IL135318A0 (en) 2001-05-20
EP1854471A1 (en) 2007-11-14
ES2331808T3 (es) 2010-01-15
PT1019073E (pt) 2008-04-21

Similar Documents

Publication Publication Date Title
HUP0002381A1 (hu) Apolipoprotein A-1 agonista hatású peptidszármazékok, ezek lipidekkel alkotott komplexei, valamint ezeket tartalmazó gyógyászati készítmények
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
DK0831773T3 (da) Suspenderede peptid/proteinformuleringer
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
ITRM960810A0 (it) Composizioni farmaceutiche contenenti ciclosporine o macrolidi
HUP0100100A2 (hu) Hepatitis C inhibitor peptid-analógok, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
AU541747B2 (en) N-(vinblastinoyl-23)derivatives of amino acid and peptides
NO954342L (no) Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav
NO20001020D0 (no) Deutererte cyklosporinanaloger og deres anvendelse som immunomodulerende midler
EP1484339A3 (en) Kallikrein-inhibiting &#34;Kunitz Domain&#34; proteins and nucleic acids encoding the same
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
ATE295372T1 (de) Hydrophobisch-modifizierte hedgehog protein zusammensetzungen und verfahren
HUP9900935A2 (hu) Baktériumellenes és gombaellenes hatású peptid és eljárás az előállítására
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
BR0312889A (pt) Polipeptìdeo t20 peguilado
BR9407693A (pt) Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto
HUP9904638A2 (hu) Szubsztituált benzopiránszármazékok alkalmazása gyógyszerkészítmények előállítására
DK0614910T3 (da) Renset form af streptograminer, dens fremstilling og farmaceutiske præparater indeholdende denne form
TW371661B (en) Novel intermediates and their use to prepare N,N&#39;-bridged bisindolylmaleimides
FR2766489B1 (fr) Derives de streptogramines, leur preparation et les compositions qui les contiennent
IT1277338B1 (it) Composizioni farmaceutiche di ciclosporina o altre sostanze peptidiche
ATE276272T1 (de) Entzündungshemmende peptide
DE69623464D1 (de) Modifizierte kojibioside analoge
DE69922150D1 (de) Deoxyhypusin reagenz und peptide
FI940717A0 (fi) Streptogramiinien puhdistetut muodot, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees